Trajan Wealth LLC Purchases New Position in Stryker Corporation $SYK

Trajan Wealth LLC acquired a new position in Stryker Corporation (NYSE:SYK) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 26,392 shares of the medical technology company’s stock, valued at approximately $8,309,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Sankala Group LLC bought a new position in shares of Stryker in the 4th quarter worth about $26,000. Godfrey Financial Associates Inc. bought a new stake in Stryker during the fourth quarter worth about $26,000. United Financial Planning Group LLC bought a new stake in Stryker during the third quarter worth about $27,000. Atlas Capital Advisors Inc. purchased a new stake in Stryker in the fourth quarter worth about $27,000. Finally, Gables Capital Management Inc. purchased a new stake in Stryker in the second quarter worth about $25,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the transaction, the director owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. This represents a 2.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 355,370 shares of company stock valued at $119,447,201 over the last ninety days. Insiders own 4.60% of the company’s stock.

Stryker Trading Down 0.5%

NYSE:SYK opened at $327.80 on Tuesday. The stock has a market cap of $125.73 billion, a price-to-earnings ratio of 33.97, a PEG ratio of 2.10 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The company’s 50 day moving average price is $327.39 and its 200-day moving average price is $332.16. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the previous year, the business earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.

Analyst Ratings Changes

Several research firms have recently issued reports on SYK. Wells Fargo & Company lowered their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Argus set a $370.00 price objective on Stryker in a research report on Thursday, July 9th. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a research note on Friday, May 1st. Needham & Company LLC cut their target price on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Finally, UBS Group began coverage on Stryker in a report on Tuesday, July 28th. They set a “buy” rating and a $400.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.